A bioactive molecule may protect against congestive heart failure after heart attacks

September 6, 2017 by Jeff Hansen, University of Alabama at Birmingham
Ganesh Halade. Credit: UAB

Heart attacks provoke an acute immune response. Leukocytes rush to the heart muscle to remove dead cells and begin building scar tissue. This is followed by a second immune response, the resolving phase that allows healing.

Too often, though, low-grade acute inflammation continues in patients long after heart , leading to and death. In a paper published in Scientific Reports, Ganesh Halade, Ph.D., and colleagues show that giving mice a form of the fatty acid-derived bioactive molecule called lipoxin improved heart function after a , as the lipoxin prompted early activation of the resolving phase of the without altering the acute phase.

This suggests lipoxin may have high therapeutic potential to limit the edema of the heart's left ventricle that leads to congestive heart failure and death. Some 2 to 17 percent of patients die one year after a heart attack, and more than 50 percent die within five years.

Halade, an assistant professor in the University of Alabama at Birmingham Department of Medicine, used a form of lipoxin called 15-epimer lipoxin A4, which is also known as aspirin-trigger lipoxin A4. The lipoxin—or the lipoxin packaged inside of liposomes to protect it in the bloodstream—was directly injected into mice after heart attacks.

The researchers followed the effect of lipoxin treatment by measuring heart function and lung edema; functioning of the spleen and kidneys, organs that are also affected by the acute immune response to heart attacks; neutrophil clearance in the resolving phase of the immune response; the activation or inhibition of receptors on macrophages; changes in pro-resolving gene markers in the left ventricle, spleen and kidneys; changes in interleukin levels; and the transition of fibroblasts into secretory myofibroblasts that deposit collagen and lead to scar formation.

Both lipoxin and the liposome-packaged lipoxin showed beneficial effects.

Key findings were: 1) Lipoxin activated the formyl peptide receptor 2, or FPR2, and GPR120 on reparative macrophages but inhibited GPR40 on inflamed macrophages in petri-dish experiments, 2) Lipoxin-injected mice had reduced left ventricle and lung mass-to-body-weight ratios, and an improved ejection fraction five days after heart attacks, 3) During the first day after heart attack, which is the acute phase of inflammation, lipoxin primed infiltration of neutrophils to the with a robust increase of Ccl2 and FPR2 expression, and 4) During the resolving phase, lipoxin initiated rapid neutrophil clearance and persistent activation of FPR2 in the .

Of additional interest, lipoxin-injected mice also had less kidney inflammation along with decreased levels of the kidney-injury biomarkers NGAL and KIM-1.

Explore further: Resolvin D1 reduces post-heart-attack heart failure

More information: Vasundhara Kain et al, Resolution Agonist 15-epi-Lipoxin A4 Programs Early Activation of Resolving Phase in Post-Myocardial Infarction Healing, Scientific Reports (2017). DOI: 10.1038/s41598-017-10441-8

Related Stories

Resolvin D1 reduces post-heart-attack heart failure

April 29, 2015
Chronic inflammation provokes a downward spiral in many diseases, including congestive heart failure, atherosclerosis and peripheral artery disease. A University of Alabama at Birmingham-led research team has now found that ...

Mice with missing lipid-modifying enzyme heal better after heart attack

May 1, 2017
Two immune responses are important for recovery after a heart attack—an acute inflammatory response that attracts leukocyte immune cells to remove dead tissue, followed by a resolving response that allows healing.

Scientists discover molecule that does double duty in stopping asthma attacks

February 27, 2013
Scientists from Brigham and Women's Hospital are on the brink of the next treatment advancement that may spell relief for the nearly nineteen million adults and seven million children in the United States suffering from asthma. ...

White blood cell research shows how causing and conquering inflammation are inextricably linked

August 18, 2014
Hugely popular non-steroidal anti-inflammation drugs like aspirin, naproxen (marketed as Aleve) and ibuprofen (Advil, Motrin) all work by inhibiting or killing an enzyme called cyclooxygenase – a key catalyst in production ...

How a Mediterranean-style diet may reduce heart failure in the aged

November 17, 2016
In mouse experiments, University of Alabama at Birmingham researchers have shown how aging and excess dietary fat create signals that lead to heart failure after a heart attack.

Activated T-cells drive post-heart attack heart failure

February 28, 2017
Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells—part of the immune system's inflammatory response—are ...

Recommended for you

Eating yogurt may reduce cardiovascular disease risk

February 15, 2018
A new study in the American Journal of Hypertension, published by Oxford University Press, suggests that higher yogurt intake is associated with lower cardiovascular disease risk among hypertensive men and women.

Newly discovered gene may protect against heart disease

February 14, 2018
Scientists have identified a gene that may play a protective role in preventing heart disease. Their research revealed that the gene, called MeXis, acts within key cells inside clogged arteries to help remove excess cholesterol ...

Blood thinners may raise stroke risk in over-65s with kidney disease

February 14, 2018
People over 65 years old may be increasing their stroke risk by taking anticoagulants for an irregular heartbeat if they also have chronic kidney disease, finds a new study led by UCL, St George's, University of London and ...

Cardiac macrophages found to contribute to a currently untreatable type of heart failure

February 14, 2018
A team of Massachusetts General Hospital (MGH) investigators has discovered, for the first time, that the immune cells called macrophages contribute to a type of heart failure for which there currently is no effective treatment. ...

Study maps molecular mechanisms crucial for new approach to heart disease therapy

February 13, 2018
Creating new healthy heart muscle cells within a patient's own ailing heart. This is how scientists hope to reverse heart disease one day. Today, a new study led by UNC-Chapel Hill researchers reveals key molecular details ...

Quality toolkit improves care in Indian hospitals

February 13, 2018
A simple toolkit of checklists, education materials and quality and performance reporting improved the quality of care but not outcomes in hospitals in the south Indian state of Kerala and may have the potential to improve ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.